Recurrent hematological toxicity after second-line treatment in patients with glioblastoma: indication of a potential predisposition
First-line myelotoxicity for glioblastoma predicts its recurrence and earlier onset in second-line therapy. Patients with toxicity in first-line have an increased risk of severe hematological toxicity upon re-exposure. Lomustine carries a higher risk for myelotoxicity than temozolomide. These findings suggest an inherent predisposition to alkylating chemotherapy-induced myelotoxicity for a subgroup of patients. Integrating prior myelotoxicity history into second-line treatment decisions may improve risk stratification and guide monitoring.
Authors
- Jan Buter (ORCID: https://orcid.org/0000-0002-2929-1070)
- W. Peter Vandertop (ORCID: https://orcid.org/0000-0001-5417-0265)
- Nathalie Grün
- Leon van Hout (ORCID: https://orcid.org/0009-0007-3040-6692)
- Frank J. Lagerwaard (ORCID: https://orcid.org/0000-0002-8740-2517)
- Mathilde C.M. Kouwenhoven (ORCID: https://orcid.org/0000-0001-5252-4365)
- Birgit I. Lissenberg‐Witte (ORCID: https://orcid.org/0000-0001-9448-1826)
- Martinus P G Broen (ORCID: https://orcid.org/0000-0002-8834-2202)
- A. Bruynzeel (ORCID: https://orcid.org/0000-0002-7542-8920)
- Bart A. Westerman (ORCID: https://orcid.org/0000-0002-9898-9616)
- F E L van den Elzen
- Z. de Jong
- Imke H. Bartelink (ORCID: https://orcid.org/0000-0001-9602-3407)
Institutions
- European Organisation for Research and Treatment of Cancer (NL)
- Dutch Cancer Society (NL)
- Maastricht University Medical Centre (NL)
- Amsterdam Neuroscience (NL)
- Amsterdam University Medical Centers (NL)
- Cancer Center Amsterdam (NL)
- Vrije Universiteit Amsterdam (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1093/oncolo/oyaf411
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00